Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3056
Source ID: NCT01319357
Associated Drug: Saxagliptin
Title: Effects of Saxagliptin on Endothelial Function
Acronym: ESENDI
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: Saxagliptin|DRUG: Placebo
Outcome Measures: Primary: effect of saxagliptin compared to placebo on endothelial and vascular function of the retinal circulation, retinal circulation. By applying Scanning-Laser-Doppler-Flowmetry, the change of retinal capillary flow after i.v. L-NMMA application, after 6 weeks of treatment with saxagliptin vs. 6 weeks of treatment with placebo (12 weeks in all) |
Sponsor/Collaborators: Sponsor: University of Erlangen-Nürnberg Medical School
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 52
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2010-10
Completion Date: 2013-04
Results First Posted:
Last Update Posted: 2014-02-12
Locations: Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Erlangen, 91054, Germany
URL: https://clinicaltrials.gov/show/NCT01319357